News – CMS

2026-11-04

CMS: Ruxolitinib Phosphate Cream Approved in Singapore, Filling Gap in Vitiligo Treatment

Ruxolitinib phosphate cream is the first and only topical prescription drug in Singapore that directly targets the pathophysiological mechanism of vitiligo. It is also the first drug specifically for repigmentation in non-segmental vitiligo, filling a decades-long void in the field and offering new hope for patients. China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Rxilient Medical received approval from the Health Sciences Authority of Singapore (HSA) on 3 November 2026 for the New Drug Application (NDA) of ruxolitinib phosphate cream (the “Product” or “Lumirix®”) for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. It is the first and only topical prescription drug in Singapore that directly targets the pathophysiological mechanism of vitiligo[1], meeting a long-standing unmet clinical need. This approval fills a gap in the field of vitiligo treatment in Singapore. In addition to Singapore, Rxilient Medical has already launched sales of […]

Learn More

2026-09-14

China Medical System’s Innovative Drug Highly Selective TYK2 Inhibitor CMS-D001 is Approved for Drug Clinical Trials for Systemic Lupus Erythematosus

CMS-D001 is an oral highly selective TYK2 inhibitor. Compared with pan-JAK inhibitors, it has less impact on other JAK family kinases,and, is expected to lower safety risks while maintaining efficacy. Compared with marketed injectable biologics, it offers the advantages of oral administration and no risk of anti-drug antibody formation, providing potential treatment convenience for patients. If approved, CMS-D001 will provide a new treatment option for patients with SLE in Chinaand create strong synergies with innovative drugs such as Metoject, further enhancing the Group’s competitiveness in the field of autoimmune diseases. China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that, on 11 September 2026, the innovative drug CMS-D001 Tablets (“CMS-D001” or the “Product”) has been granted the Drug Clinical Trial Approval Notice by the National Medical Products Administration of the People’s Republic of China (“NMPA”). The approval notice was obtained on 14 September 2026. The NMPA grants consent to conduct clinical trials evaluating the safety and efficacy […]

Learn More

2026-09-09

CMS: Initial Prescriptions for Silevimig Injection, the World’s First Bispecific Antibody Against Rabies, Issued in China, Accelerating Clinical Application

On 9 September, China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that the initial prescriptions for the Class 1 innovative drug Silevimig Injection (the “Product”) have recently been issued in multiple hospitals across China, including Beijing Luhe Hospital of Capital Medical University, Wenzhou People’s Hospital, Kaiping Central Hospital, Dongguan Guangji Hospital and Huidong Jilong Ankang Hospital. This marks that the world’s first bispecific antibody for passive immunization against rabies has officially commenced its large-scale clinical application, offering a better solution for urgent post-exposure management against rabies in China. Dual-Epitope Neutralization with Low Dosing, Addressing Clinical Pain Points Silevimig Injection is the world’s first fully human bispecific antibody targeting dual epitopes (G protein epitopes I and III) of the rabies virus, which is consistent with the World Health Organization (“WHO”) recommendation for a “cocktail” therapeutic paradigm. It can effectively neutralize different viral strains or genotypes of the rabies virus, […]

Learn More

All News

Company News

Latest News

CMS: Ruxolitinib Phosphate Cream Approved in Singapore, Filling Gap in Vitiligo Treatment

China Medical System’s Innovative Drug Highly Selective TYK2 Inhibitor CMS-D001 is Approved for Drug Clinical Trials for Systemic Lupus Erythematosus

CMS: Initial Prescriptions for Silevimig Injection, the World’s First Bispecific Antibody Against Rabies, Issued in China, Accelerating Clinical Application

All News